Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.36 USD | -5.62% | +4.35% | -12.50% |
Apr. 04 | Acumen Pharmaceuticals Signs Deal With Lonza to Manufacture Alzheimer's Treatment Drug | MT |
Apr. 04 | Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 202M |
---|---|---|---|---|---|
Net income 2024 * | -68M | Net income 2025 * | -93M | EV / Sales 2024 * | - |
Net cash position 2024 * | 121M | Net cash position 2025 * | 258M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.75
x | P/E ratio 2025 * |
-2.12
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.87% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | -5.62% | ||
1 week | +4.35% | ||
Current month | +4.35% | ||
1 month | -12.73% | ||
3 months | +7.01% | ||
6 months | +60.77% | ||
Current year | -12.50% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 55 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 3.36 | -5.62% | 140,393 |
24-05-06 | 3.56 | +2.01% | 177,331 |
24-05-03 | 3.49 | +0.29% | 247,725 |
24-05-02 | 3.48 | +7.08% | 235,476 |
24-05-01 | 3.25 | +0.93% | 195,492 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.50% | 214M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- ABOS Stock